Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-247.92%
operating margin TTM
-282.71%
revenue TTM
15.07 Million
revenue per share TTM
0.17$
valuation ratios | |
|---|---|
| pe ratio | -7.53 |
| peg ratio | -0.74 |
| price to book ratio | 2.09 |
| price to sales ratio | 18.78 |
| enterprise value multiple | -7.08 |
| price fair value | 2.09 |
profitability ratios | |
|---|---|
| gross profit margin | 100.0% |
| operating profit margin | -282.71% |
| pretax profit margin | -247.43% |
| net profit margin | -247.92% |
| return on assets | -21.36% |
| return on equity | -26.68% |
| return on capital employed | -26.61% |
liquidity ratios | |
|---|---|
| current ratio | 9.84 |
| quick ratio | 9.84 |
| cash ratio | 1.86 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 9.65 |
| days of payables outstanding | 0.00 |
| cash conversion cycle | 9.65 |
| receivables turnover | 37.83 |
| payables turnover | 0.00 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.11 |
| debt equity ratio | 0.14 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.13 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -1.58 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.26 |
| cash per share | 5.60 |
| operating cash flow per share | -1.22 |
| free cash flow operating cash flow ratio | 1.03 |
| cash flow coverage ratios | -1.58 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -30.53 |
Frequently Asked Questions
When was the last time Verve Therapeutics, Inc. (NASDAQ:VERV) reported earnings?
Verve Therapeutics, Inc. (VERV) published its most recent earnings results on 14-05-2025.
What is Verve Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Verve Therapeutics, Inc. (NASDAQ:VERV)'s trailing twelve months ROE is -26.68%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Verve Therapeutics, Inc. (VERV) currently has a ROA of -21.36%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did VERV's net profit margin stand at?
VERV reported a profit margin of -247.92% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is VERV's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 9.84 in the most recent quarter. The quick ratio stood at 9.84, with a Debt/Eq ratio of 0.14.